Publicaciones en las que colabora con María D. Odero (47)

2023

  1. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

    Blood, Vol. 141, Núm. 9, pp. 1047-1059

  2. Regulation and role of the PP2A-B56 holoenzyme family in cancer

    Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1878, Núm. 5

  3. Set Protein Is Involved in FLT3 Membrane Trafficking

    Cancers, Vol. 15, Núm. 8

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  2. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2020

  1. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia

    Blood Cancer Journal, Vol. 10, Núm. 1

  2. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity

    Cancer Letters, Vol. 468, pp. 1-13

2017

  1. MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia

    Oncotarget, Vol. 8, Núm. 33, pp. 53989-54003

2016

  1. Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia

    Frontiers in Oncology, Vol. 6, Núm. APR

2014

  1. Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels

    Journal of Hematology and Oncology, Vol. 7, Núm. 1

2013

  1. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription

    Oncogene, Vol. 32, Núm. 16, pp. 2069-2078

2012

  1. Epigenetic regulation of miRNA genes in acute leukemia

    Leukemia, Vol. 26, Núm. 3, pp. 395-403

  2. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics

    PLoS ONE, Vol. 7, Núm. 8

  3. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities

    Leukemia

  4. The role of the GATA2 transcription factor in normal and malignant hematopoiesis

    Critical Reviews in Oncology/Hematology, Vol. 82, Núm. 1, pp. 1-17

2011

  1. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

    Haematologica, Vol. 96, Núm. 10, pp. 1448-1456

  2. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas

    PLoS ONE, Vol. 6, Núm. 10

  3. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

    Leukemia, Vol. 25, Núm. 4, pp. 606-614

2010

  1. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2

    British Journal of Cancer, Vol. 103, Núm. 8, pp. 1292-1296

  2. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

    Blood, Vol. 115, Núm. 3, pp. 615-625